Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ibd/izaf002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Upadacitinib in Autoimmune Enteropathy-A Case Report.
Inflamm Bowel Dis
February 2025
Department of Gastroenterology, Austin Health, Melbourne, VIC, Australia.
Successful treatment of concurrent atopic dermatitis and psoriatic arthritis with upadacitinib.
Ital J Dermatol Venerol
December 2024
Unit of Dermatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Pregnancy Outcomes of Targeted Synthetic Disease-Modifying Antirheumatic Drugs Among Patients With Autoimmune Diseases: A Scoping Review.
Arthritis Care Res (Hoboken)
February 2025
University of British Columbia, Collaboration for Outcomes Research and Evaluation, Arthritis Research Canada, and Centre for Health Evaluation and Outcome Sciences, Vancouver, British Columbia, Canada.
Objective: Targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) have expanded the management of autoimmune diseases, including rheumatic diseases. As the use of these drugs grows, it is important to understand their effects on pregnancy. We conducted a scoping review to synthesize the current evidence on the impacts of tsDMARDs on pregnancy outcomes.
View Article and Find Full Text PDFAntiphospholipid syndrome is an autoimmune disease characterised by thrombotic and/or obstetric manifestations with persistent antiphospholipid antibodies. Diagnosis involves confirming the persistence of antiphospholipid antibodies in symptomatic patients, using validated classification criteria as a guide. The likelihood of obtaining false-positive or false-negative test results in certain settings, and the lack of standardisation between laboratory methods, are important considerations.
View Article and Find Full Text PDFGastrointestinal Perforations Associated With JAK Inhibitors: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
United European Gastroenterol J
December 2024
The Sheba Talpiot Medical Leadership Program, Sheba Medical Center, Ramat-Gan, Israel.
Background: Gastrointestinal perforations have been reported in a small number of rheumatoid arthritis (RA) patients treated with Janus kinase (JAK) inhibitors in clinical trials. However, large-scale postmarketing data repositories are needed to further investigate this potentially rare but serious adverse event.
Methods: A retrospective, pharmacovigilance study of the FDA adverse event reporting system (July 2014 to September 2023) assessing the reporting of gastrointestinal perforations following JAK inhibitors compared to biological disease-modifying antirheumatic drugs (bDMARDs) in RA patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!